Coeptis Therapeutics Warrants
COEPW
COEPW was delisted on the 24th of April, 2026.
23 hedge funds and large institutions have $843K invested in Coeptis Therapeutics Warrants in 2022 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 4 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
15% less funds holding
Funds holding: 27 → 23 (-4)
18% less capital invested
Capital invested by funds: $1.03M → $843K (-$184K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SIA
SkyView Investment Advisors
Shrewsbury,
New Jersey
|
+$1.68K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$134 |
| 3 |
HF
HRT Financial
New York
|
+$5 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFM
Boothbay Fund Management
New York
|
-$151K |
| 2 |
MC
Meteora Capital
Boca Raton,
Florida
|
-$18K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.13K |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
-$1K |
| 5 |
LCM
Landscape Capital Management
Englewood,
New Jersey
|
-$130 |
COEPW Hedge Fund Activity: Q3 2022 in Review
23 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Coeptis Therapeutics Warrants (COEPW) for Q3 2022, worth a combined $843K — down 18% from $1.03M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of COEPW and 0 opened new positions — a net loss of 4 holders — while 2 trimmed existing stakes and 3 added.
The largest buyer was SkyView Investment Advisors, adding an estimated $1.68K. The largest seller was Boothbay Fund Management, exiting entirely with an estimated $151K sold.
- 23 institutional investors held Coeptis Therapeutics Warrants (COEPW) as of Q3 2022, down from 27 in Q2 2022.
- Funds reported $843K of Coeptis Therapeutics Warrants stock for Q3 2022, down 18% quarter-over-quarter.
- 0 funds opened new Coeptis Therapeutics Warrants positions in Q3 2022 and 4 closed out, a net change of -4 holders.
- The largest Coeptis Therapeutics Warrants buyer in Q3 2022 was SkyView Investment Advisors, an estimated $1.68K added.
- The largest Coeptis Therapeutics Warrants seller in Q3 2022 was Boothbay Fund Management, an estimated $151K sold.
Based on aggregated 13F filings for Q3 2022.